Latest news with #StatenIsland
CBS News
2 hours ago
- Entertainment
- CBS News
NYC Summer Streets 2025 start this Saturday. Maps show which blocks will be car-free.
New York City's Summer Streets program returns this weekend, starting in Queens and Staten Island. Several blocks will be shut down to vehicle traffic on Saturday for people to enjoy car-free time outside. Visitors can expect live entertainment, fitness and art activities for the whole family. Lyft is also offering free Citi Bike day passes with the promo code: LYFTSUMMER25. The city's Summer Streets program has been around since 2008 and it continues to expand. This year, the Manhattan location will stretch the entire length of the borough, from Inwood to the Brooklyn Bridge. The first weekend kicks off this Saturday from 7 a.m. to 3 p.m. Organizers say it's rain or shine. Manhattan is up next on August 2, 9 and 16, followed by Brooklyn and the Bronx on August 23. The Summer Streets are in addition to what the city calls "Open Streets" throughout the year. Vernon Boulevard will be closed from 44th Drive in Long Island City to 30th Road in Astoria. This location will feature performances from several cultural organizations, as well as yoga and Zumba classes. There will also be a "NYRR Start Line Series," where people can run or walk a 2.5-mile course, and public art will be on display. The following streets will be closed to vehicle traffic: The Staten Island location is along Forest Avenue in West Brighton. The roadway will be closed from Elizabeth Street to Bard Avenue. This location will also have performances from different groups, including the Staten Island Musical Steppers and Richmond County Orchestra, as well as public art. These streets will be closed around the area: CLICK HERE for the complete Summer Streets maps and more information.
Yahoo
a day ago
- Business
- Yahoo
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2025 financial results on Tuesday, August 12, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, August 12, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference ID: 13755161 International: Click here for participant international Toll-Free access numbers About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®™) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. Acurx previously announced that it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year subject to obtaining appropriate financing. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel. To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact:Acurx Pharmaceuticals, P. Luci, President & CEOTel: 917-533-1469Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc.
Yahoo
2 days ago
- Yahoo
N.Y.C. Uncle Faces Assault Charge After Allegedly Throwing 1-Year-Old Niece Down Trash Chute
A New York City man was arrested after police say he threw his 1-year-old niece down a garbage chute, PEOPLE has learned.A spokesperson with the New York City Police Department confirmed with PEOPLE that Aaron Henderson, 39, has been charged with three counts of assault, two counts of unlawful imprisonment, and one count of endangering the welfare of a child. The NYPD spokesperson said officers responded to an apartment building at 195 Steuben St in the Park Hill neighborhood of Staten Island shortly after receiving a 911 call around 3 p.m. on Monday, July 21. 'Upon arrival, officers were informed that a 39-year-old male placed a 1-year-old female inside of a garbage chute,' the NYPD spokesperson said. The infant suffered a "minor abrasion to the torso" and was taken to Staten Island University North Campus hospital in stable condition. The New York Daily News reported that Henderson has autism, and that the girl's parents rushed downstairs to help rescue their child after realizing what had happened. Want to keep up with the latest crime coverage? Sign up for for breaking crime news, ongoing trial coverage and details of intriguing unsolved cases. WABC reported that the baby girl fell down the chute from the third floor of the apartment building, landing on the first floor. The outlet reported that police described Henderson, the girl's uncle, as 'emotionally disturbed' at the time of his arrest. Neighbors appeared stunned by the news, according to the outlet. 'I've been here for over 20 years, it's saddening,' neighbor Milton Franklin told WABC from his apartment door, explaining that he had seen the girl's mother go in the ambulance with her infant daughter, who was crying. 'I'm hurt,' Franklin added. 'I'm just going to pray that God wraps his arms around this family and that they get through the situation.' Read the original article on People
Yahoo
2 days ago
- Entertainment
- Yahoo
Pete Davidson Breaks Silence On Becoming A Dad In First Interview Since Baby News
Pete Davidson is going to be a dad! The 31-year-old 'King of Staten Island' star spoke about his brand-new baby news for the first time during an appearance on 'The Tonight Show' with Jimmy Fallon. 'I did it!' Davidson said jokingly as the audience applauded, before expressing his sincere excitement. 'Nah, if anybody who knows me, it's my dream to be a dad, so I'm so excited,' he said, adding this his girlfriend, model Elsie Hewitt, is also giddy. 'I'm excited to see her be a mom, so we're stoked,' he said. Davidson added that the news put things in perspective, as 'everything else doesn't really matter anymore.' 'It's nice,' the former 'Saturday Night Live' cast member added. Fallon heaped praise on Davidson, saying that he's going to be a 'fantastic dad.' Hewitt and Davidson reportedly began seeing each other in March. Hewitt announced the baby news last week in an Instagram post. 'Welp now everyone knows we had sex,' she captioned her post, which showed the couple posing together, alongside a photo of an ultrasound. TMZ was the first to report the news, and said the couple's baby is due sometime in the winter. Davidson, who lost his own father in the Sept. 11, 2001, attacks, has spoken about his 'dream' of being a dad before. 'My favorite thing ever, which I have yet to achieve is, I wanna have a kid. That's, like, my dream,' Davidson said in a sit-down for Kevin Hart's show, 'Hart to Hart' in 2022. The 'SNL' star said that he was 'so excited for that chapter' in his life. 'That's kind of what I'm just preparing for now, is just trying to be as good as a dude and develop and get better so when that happens it's just easier,' he explained.
The Standard
2 days ago
- Business
- The Standard
Amazon shuts down Shanghai AI research lab, FT says
The Amazon logo is seen outside its JFK8 distribution center in Staten Island, New York, U.S. November 25, 2020. REUTERS/Brendan McDermid/File Photo
